Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | PDK1 | Q15118 | 6/20 | 0.59 |
| ▸ | PDK2 | Q15119 | 6/20 | 0.59 |
| ▸ | PDK3 | Q15120 | 6/20 | 0.59 |
| ▸ | PDK4 | Q16654 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30366703 | 1.00 | NOTUM (0.71) | NOTUMTSHRPDK1PDK2PDK3 | |
| SCHEMBL30366447 | 1.00 | NOTUM (0.71) | NOTUMTSHRPDK1PDK2PDK3 | |
| SCHEMBL17018045 | 1.00 | NOTUM (0.71) | NOTUMTSHRPDK1PDK2PDK3 | |
| SCHEMBL20462833 | 0.87 | TSHR (0.62) | NOTUMTSHRPDK1PDK2PDK3 | |
| SCHEMBL7785444 | 0.85 | TSHR (0.60) | NOTUMTSHRPDK1PDK2PDK3 | |
| Lithium Ion SCHEMBL22092468 | 0.84 | TSHR (0.59) | NOTUMTSHRPDK1PDK2PDK3 | |
| Lithium Ion SCHEMBL30437889 | 0.84 | TSHR (0.59) | NOTUMTSHRPDK1PDK2PDK3 | |
| SCHEMBL24953447 | 0.83 | POLB (0.56) | NOTUMTSHRPDK1PDK2PDK3 | |
| SCHEMBL2586534 | 0.83 | NOTUM (1.00) | NOTUMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10167044 | 0.83 | NOTUM (1.00) | NOTUMMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MONASH UNIVERSITY (AU) | 2023-10-05 | — | — | US | disclosed |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MONASH UNIVERSITY (AU) | 2023-10-05 | — | — | US | disclosed |
| US-11666580-B2 | Mechanism of resistance to bet bromodomain inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666580-B2 | Mechanism of resistance to bet bromodomain inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11369638-B2 | — | — | 2022-06-28 | — | — | US | disclosed |
| WO-2021152149-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2021-08-05 | — | — | WO | disclosed |
| US-20200368248-A1 | MECHANISM OF RESISTANCE TO BET BROMODOMAIN INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10426799-B2 | Methods for production of platelets from pluripotent stem cells and compositions thereof | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) | 2019-10-01 | — | — | US | disclosed |
| US-9993503-B2 | Methods for production of platelets from pluripotent stem cells and compositions thereof | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) | 2018-06-12 | — | — | US | disclosed |
| WO-2013033270-A2 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20120252139-A1 | Novel Process | GLAXOSMITHKLINE LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120252139-A1 | Novel Process | GLAXOSMITHKLINE LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120252139-A1 | Novel Process | GLAXOSMITHKLINE LLC | 2012-10-04 | — | — | US | disclosed |
| EP-2496945-A1 | NOVEL PROCESS | GlaxoSmithKline LLC (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011054851-A1 | NOVEL PROCESS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054851-A1 | NOVEL PROCESS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20100204282-A1 | Reverse indoles as 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2007084625-A9 | NOVEL COMPOUNDS AND METHODS FOR INHIBITING P53 ACTIVITY | SINAI SCHOOL MEDICINE (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007084625-A2 | NOVEL COMPOUNDS AND METHODS FOR INHIBITING P53 ACTIVITY | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204282-A1 | Reverse indoles as 5-lipoxygenase-activating protein (FLAP) inhibitors | ALOX5, LTC4S, LTA4H | NOTUM 302/4885TSHR 3772/4885PDK1 2106/4885 |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | NOTUM 2058/4885TSHR 3711/4885PDK1 2163/4885 |
| US-11666580-B2 | Mechanism of resistance to bet bromodomain inhibitors | BET1, BRD2, BRD4 | NOTUM 3487/4885TSHR 4104/4885PDK1 2639/4885 |
| US-10426799-B2 | Methods for production of platelets from pluripotent stem cells and compositions thereof | THPO, PDGFRA, PDGFRB | NOTUM 4144/4885TSHR 4224/4885PDK1 2196/4885 |
| US-20200368248-A1 | MECHANISM OF RESISTANCE TO BET BROMODOMAIN INHIBITORS | BET1, BRD2, BRD4 | NOTUM 3487/4885TSHR 4104/4885PDK1 2639/4885 |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MAP2K2, BRPF3, BRDT | NOTUM 4466/4885TSHR 3349/4885PDK1 540/4885 |
| US-11369638-B2 | — | THPO, PDGFRA, PDGFA | NOTUM 4138/4885TSHR 4325/4885PDK1 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.